Table 2.

Summary of current therapies and the new therapeutic approach in the treatment of neuroblastoma and high-risk neuroblastoma.

Therapy	Therapeutic Strategy	Availability
Surgical Resection	Tumor mass removal by surgical resection	Standard Medical Practice
Multimodal Chemotherapy	Tumor cell elimination using non-specific chemical agents	Standard Medical Practice
Autologous stem cell transplantation	Stem cell reinfusion after high dose chemotherapy	Standard Medical Practice
Radiation Therapy	Tumor mass removal by radiations	Standard Medical Practice
Anti-GD2 Immunotherapy	Induction of immune system stimulation	Standard Medical Practice
Isotretinoin	Induction of tumor cell differentiation and proliferation arrest	Standard Medical Practice
BET Inhibitors	Inhibition of specific molecular pathway related to MYCN	Clinical Studies
HDACs Inhibitors	Inhibition of specific molecular pathway related to MYCN	Clinical Studies
PI3K/mTOR Inhibitors	Inhibition of specific molecular pathway related to MYCN	Clinical Studies
Aurora Kinase-A Inhibitors	Inhibition of specific molecular pathway related to MYCN	Clinical Studies
MDM2 inhibitors	Inhibition of specific molecular pathway related to MYCN	Clinical Studies
MYCN direct inhibitor	Specific MYCN expression inhibition or N-Myc protein degradation	Preclinical Studies